DIVI S LABORATORIES LTD vs Phaarmasia Ltd

A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and Phaarmasia Ltd (PHAARMASIALTD) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs PHAARMASIALTD on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability40
  • Growth01
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

95.40
P/E ratio
3.40
10.62
P/B ratio
3.32
0.33%
Dividend yield
0.00%
₹96.73
EPS
₹-2.33

Profitability

DIVISLAB takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
12.80%
22.00%
Return on capital
-16.00%
33.00%
EBITDA margin
-8.00%
24.32%
Net margin
-8.33%

Growth

PHAARMASIALTD takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
20.47%
12.10%
Profit CAGR (3Y) even

Size & financial health

DIVISLAB takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2.45L Cr
Market cap
₹65 Cr
₹10,560 Cr
Revenue
₹24 Cr
₹2,568 Cr
Net profit
₹-2 Cr
0.00
Debt / equity
0.05
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 14.6 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
Phaarmasia Ltd
  • + ["Company is almost debt free.", "Company is expected to give good quarter", "Company has delivered good profit growth of 44.8% CAGR over last 5 years", "Debtor days have improved from 60.8 to 39.7 days."]
  • ["Stock is trading at 2.95 times its book value", "Company has a low return on equity of -0.39% over last 3 years.", "Earnings include an other income of Rs.19.9 Cr.", "Working capital days have increased from -17.3 days to 62.1 days"]
DIVI S LABORATORIES LTD full analysis Phaarmasia Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

DIVISLAB vs PHAARMASIALTD: Share Price, Valuation & Which to Buy | DocStoX